-
Tytuł:
-
Xanthohumol suppresses inflammation in chondrocytes and ameliorates osteoarthritis in mice.
-
Autorzy:
-
Chen X; Department of Orthopaedics, Affiliated Hospital of Guilin Medical College, Guilin, Guangxi Province, China; Zhejiang Provincial Key Laboratory of Orthopedics, Wenzhou, Zhejiang Province, China.
Li Z; Department of Orthopaedics, Affiliated Hospital of Guilin Medical College, Guilin, Guangxi Province, China.
Hong H; The Second School of Medicine, Wenzhou Medical University. Wenzhou, Zhejiang Province, China.
Wang N; Department of Orthopaedics, Affiliated Hospital of Guilin Medical College, Guilin, Guangxi Province, China.
Chen J; Department of Orthopaedics, Affiliated Hospital of Guilin Medical College, Guilin, Guangxi Province, China.
Lu S; The Second School of Medicine, Wenzhou Medical University. Wenzhou, Zhejiang Province, China.
Zhang H; The Second School of Medicine, Wenzhou Medical University. Wenzhou, Zhejiang Province, China.
Zhang X; Department of Orthopaedics, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China; Zhejiang Provincial Key Laboratory of Orthopedics, Wenzhou, Zhejiang Province, China; The Second School of Medicine, Wenzhou Medical University. Wenzhou, Zhejiang Province, China. Electronic address: .
Bei C; Department of Orthopaedics, Affiliated Hospital of Guilin Medical College, Guilin, Guangxi Province, China. Electronic address: .
-
Źródło:
-
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2021 May; Vol. 137, pp. 111238. Date of Electronic Publication: 2021 Jan 28.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Paris : Editions Scientifiques Elsevier
Original Publication: New York, N.Y. : Masson Pub. USA, Inc., c1982-
-
MeSH Terms:
-
Anti-Inflammatory Agents/*pharmacology
Chondrocytes/*drug effects
Flavonoids/*pharmacology
Inflammation Mediators/*metabolism
Joints/*drug effects
Osteoarthritis/*drug therapy
Propiophenones/*pharmacology
Animals ; Cells, Cultured ; Chondrocytes/metabolism ; Chondrocytes/pathology ; Cyclooxygenase 2/metabolism ; Cytokines/metabolism ; Disease Models, Animal ; Joints/metabolism ; Joints/pathology ; Male ; Mice, Inbred C57BL ; NF-E2-Related Factor 2/metabolism ; NF-kappa B/metabolism ; Nitric Oxide/metabolism ; Nitric Oxide Synthase Type II/metabolism ; Osteoarthritis/metabolism ; Osteoarthritis/pathology ; Signal Transduction
-
Contributed Indexing:
-
Keywords: Inflammation; NF-кB; Nrf2; Osteoarthritis; Xanthohumol
-
Substance Nomenclature:
-
0 (Anti-Inflammatory Agents)
0 (Cytokines)
0 (Flavonoids)
0 (Inflammation Mediators)
0 (NF-E2-Related Factor 2)
0 (NF-kappa B)
0 (Nfe2l2 protein, mouse)
0 (Propiophenones)
31C4KY9ESH (Nitric Oxide)
EC 1.14.13.39 (Nitric Oxide Synthase Type II)
EC 1.14.13.39 (Nos2 protein, mouse)
EC 1.14.99.- (Ptgs2 protein, mouse)
EC 1.14.99.1 (Cyclooxygenase 2)
T4467YT1NT (xanthohumol)
-
Entry Date(s):
-
Date Created: 20210131 Date Completed: 20210719 Latest Revision: 20210719
-
Update Code:
-
20240104
-
DOI:
-
10.1016/j.biopha.2021.111238
-
PMID:
-
33517187
-
Osteoarthritis (OA), manifested as degeneration and damage of the articular cartilage is a progressive disease of joints. Previous studies have shown that extracellular matrix degradation and inflammation have quite a significant performance in the occurrence and development of OA. In various maladies, an anti-inflammatory effect has been demonstrated for Xanthohumol (XN); while OA is an inflammation related disease. The current in vivo and in vitro study aimed to investigate the therapeutic effect of XN on OA as well as its working mechanism. The results showed that XN has the capability to hinder the expression of nitric oxide synthase (INOS), IL-1β-promoted inducible nitric oxide (NO), necrosis factor-α of tumor (TNF-α), interleukin-6 (IL-6), and cyclooxygenase-2 (COX-2) in vitro. In addition, XN has been found to down-regulate the expression of matrix metalloproteinase-13 and prothrombin stimulated by IL-1β and up-regulates type II collagen and Aggrecan expression. At the same time, it was discovered that XN activates nuclear factor (Nrf2) in chondrocytes stimulated by IL-1β and inhibits nuclear factor B (NF-кB) signal transduction. The DMM model manifests that XN has an inhibitory impact on the progression of osteoarthritis and thus may be a candidate drug to slow down and delay the development of OA.
(Copyright © 2021 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.)
